Evaluating age as a factor for survival and quality of life in patients with BRAF V600E-mutant metastatic colorectal cancer treated with encorafenib plus cetuximab ± binimetinib: Subanalysis of BEACON CRC

被引：1
|
作者：
Ng, K. [1 ]
Ciardiello, F. [2 ]
Van Cutsem, E. [3 ,4 ]
Yaeger, R. [5 ]
Yoshino, T. [6 ]
Desai, J. [7 ]
Wasan, H. [8 ]
Alkuzweny, B. [9 ]
Zhang, X. [10 ]
Tabernero, J. [11 ,12 ]
Kopetz, S. [13 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Campania Luigi Vanvitelli, Naples, Italy
[3] Univ Hosp Gasthuisberg, Leuven, Belgium
[4] Univ Leuven, Leuven, Belgium
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[6] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[7] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[8] Imperial Coll London, Hammersmith Hosp, Div Canc, London, England
[9] Pfizer Inc, San Diego, CA USA
[10] Pfizer Inc, New York, NY USA
[11] Vall Hebron Univ Hosp, Barcelona, Spain
[12] Vall Hebron Inst Oncol, Barcelona, Spain
[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.04.435
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SO-37
引用
收藏
页码：S372 / S373
页数：2
相关论文
共 50 条
  • [41] A Phase Ib/II Study of WNT974+Encorafenib plus Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer
    Tabernero, Josep
    Van Cutsem, Eric
    Garralda, Elena
    Tai, David
    De Braud, Filippo
    Geva, Ravit
    van Bussel, Mark T. J.
    Fiorella Dotti, Katia
    Elez, Elena
    de Miguel, Maria J.
    Litwiler, Kevin
    Murphy, Danielle
    Edwards, Michelle
    Morris, Van Karlyle
    [J]. ONCOLOGIST, 2023, : 230 - 238
  • [42] Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study
    Taieb, Julien
    Lonardi, Sara
    Desai, Jayesh
    Folprecht, Gunnar
    Gallois, Claire
    Marques, Eduardo Polo
    Khan, Sadya
    Castagne, Claire
    Wasan, Harpreet
    [J]. CLINICAL COLORECTAL CANCER, 2023, 22 (01) : 59 - 66
  • [43] Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience
    Boccaccino, A.
    Borelli, B.
    Intini, R.
    Antista, M.
    Bensi, M.
    Rossini, D.
    Passardi, A.
    Tamberi, S.
    Giampieri, R.
    Antonuzzo, L.
    Noto, L.
    Roviello, G.
    Zichi, C.
    Salati, M.
    Puccini, A.
    Noto, C.
    Parisi, A.
    Rihawi, K.
    Persano, M.
    Crespi, V
    Libertini, M.
    Giordano, M.
    Moretto, R.
    Lonardi, S.
    Cremolini, C.
    [J]. ESMO OPEN, 2022, 7 (03)
  • [44] A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
    Baik, Christina
    Cheng, Michael L.
    Dietrich, Martin
    Gray, Jhanelle E.
    Karim, Nagla A.
    [J]. ADVANCES IN THERAPY, 2024, 41 (07) : 2586 - 2605
  • [45] COMPARISON OF PREDICTED OVERALL SURVIVAL TO OBSERVED CLINICAL DATA IN PATIENTS WITH BRAF V600-MUTANT METASTATIC MELANOMA TREATED WITH ENCORAFENIB ALONE OR ENCORAFENIB plus BINIMETINIB
    Hahn, E.
    Rashid, J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S19 - S19
  • [46] Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA
    Shuosha Li
    Huabin Hu
    Dong Ding
    Youwen Zhu
    Jin Huang
    [J]. Advances in Therapy, 2021, 38 : 1650 - 1659
  • [47] Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA
    Li, Shuosha
    Hu, Huabin
    Ding, Dong
    Zhu, Youwen
    Huang, Jin
    [J]. ADVANCES IN THERAPY, 2021, 38 (03) : 1650 - 1659
  • [48] Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib plus /- binimetinib or alpelisib
    Huijberts, Sanne C. F. A.
    Boelens, Mirjam C.
    Bernards, Rene
    Opdam, Frans L.
    [J]. BRITISH JOURNAL OF CANCER, 2021, 124 (01) : 176 - 182
  • [49] Influence of sex on safety and efficacy in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with encorafenib-cetuximab plus /-binimetinib (E-C plus /-B)
    Montana, F. J. Ros
    Navarro, V.
    Comas, R.
    Rodriguez, A. Garcia
    Gomez, D.
    Gonzalez, N. Saoudi
    Vicente, P.
    Cuadra, J. L.
    Paez, D.
    Alonso, V.
    Martinez, A. Hernandez
    Valbuena, D. E. Lopez
    Argota, I. Baraibar
    Ballabrera, F. Salva
    Tabernero, J.
    Fernandez, M. E. Elez
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S707 - S707
  • [50] BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib plus MEK inhibitor binimetinib plus anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer
    Van Cutsem, E.
    Cuyle, P.
    Huijberts, S.
    Schellens, J.
    Elez, E.
    Yaeger, R.
    Fakih, M.
    Montagut, C.
    Peeters, M.
    Desai, J.
    Yoshino, T.
    Ciardiello, F.
    Wasan, H.
    Maharry, K.
    Christy-Bittel, J.
    Gollerkeri, A.
    Kopetz, S.
    Grothey, A.
    Tabernero, J.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
12345